EcoDrugPlus

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSCVAG00000019115
Gene Symbol: CHRNB4
3 Cross references
194 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSCVAG00000022012
Gene Symbol: F2R
3 Cross references
211 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSCVAG00000021039
Gene Symbol: F3
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSCVAG00000004124
Gene Symbol: LOC107099184
3 Cross references
203 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSCVAG00000004149
Gene Symbol: F10
1 Cross references
244 Possible Orthologues:

Coagulation Factor X-Like

Ensembl ID : ENSCVAG00000004162
Gene Symbol: LOC107099172
3 Cross references
240 Possible Orthologues:

Coagulation Factor Xi-Like

Ensembl ID : ENSCVAG00000014751
Gene Symbol: LOC107092604
2 Cross references
205 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSCVAG00000015710
Gene Symbol: CCDC6
3 Cross references
208 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSCVAG00000018850
Gene Symbol: LOC107091375
2 Cross references
173 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSCVAG00000018842
Gene Symbol: LOC107091373
3 Cross references
312 Possible Orthologues:

Corticotropin Releasing Hormone Receptor 1

Ensembl ID : ENSCVAG00000006507
Gene Symbol: CRHR1
3 Cross references
208 Possible Orthologues:

Cyclin D1

Ensembl ID : ENSCVAG00000002852
Gene Symbol: CCND1
3 Cross references
232 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).